Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

  title={Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?},
  author={Serena Silvestro and Andrea Valeri and Emanuela Mazzon},
  journal={International Journal of Molecular Sciences},
Alzheimer’s disease (AD) is a neurodegenerative disorder affecting millions of people around the world. The two main pathological mechanisms underlying the disease are beta-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) of Tau proteins in the brain. Their reduction has been associated with slowing of cognitive decline and disease progression. Several antibodies aimed to target Aβ or Tau in order to represent hope for millions of patients, but only a small number managed… 

Figures and Tables from this paper

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Despite the controversy, the aducanumab showed to affect downstream tau pathology, which could open doors for a combination therapy approach for AD (anti-tau and anti-amyloid drug).

Amylin and Secretases in the Pathology and Treatment of Alzheimer’s Disease

The aim of this narrative review is to evaluate the contemporary literature on these protease biomolecule modulators and determine its utility in the treatment of Alzheimer’s disease.

A Narrative Review of the Effects of Citrus Peels and Extracts on Human Brain Health and Metabolism

This review summarizes the recent evidence of the beneficial effects of citrus peels and extracts on human cognition and related functions and appears to support preclinical evidence and show improved cognitive function and reduced associated disease risk in healthy individuals and/or patients.

Effects of Aducanumab on treating Alzheimer’s disease: targets and clinical trials

  • Baoyi Huang
  • Education
    Highlights in Science, Engineering and Technology
  • 2022
These instructions give you guidelines for preparing papers for DRP. Use this document as a template if you are using Microsoft Word 6.0 or later. Otherwise, use this document as an instruction set.

CIA_A_325026 797..810

  • 2022



The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.

Immunotherapy for Alzheimer’s disease: hoops and hurdles

  • C. Lemere
  • Biology
    Molecular Neurodegeneration
  • 2013
Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease.

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease

Inhibitors of tau acetylation are being actively pursued based on impressive results in animal studies obtained by salsalate, a clinically used derivative of salicylic acid.

Amyloid beta plaque: a culprit for neurodegeneration

The physiological role of Aβ must be considered in the development of medications that intended to decrease its oligomerization forming plaques in a disease like Alzheimer’s disease, as an attempt to develop future strategies for prevention of neurodegenerative disorders.

Passive immunotherapy for N-truncated tau ameliorates the cognitive deficits in two mouse Alzheimer’s disease models

The findings indicate that the 20–22 kDa NH2-terminal tau fragment is crucial target for Alzheimer’s disease therapy and prospect immunotherapy with 12A12 monoclonal antibody as safe (normal tau-preserving), beneficial approach in contrasting the early Amyloidβ-dependent and independent neuropathological and cognitive alterations in affected subjects.

Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease

Results indicate that fundamental biochemical events relevant to AD can be monitored in blood, and that the species detected may be useful clinical biomarkers for AD.

The amyloid hypothesis of Alzheimer's disease at 25 years

Although many factors contribute to AD pathogenesis, Aβ dyshomeostasis has emerged as the most extensively validated and compelling therapeutic target.

Donanemab in Early Alzheimer's Disease.

In patients with early symptomatic Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed.

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Gantenerumab is an investigational fully human anti-amyloid beta monoclonal antibody with a high capacity to bind and remove beta-amYLoid plaques in the brain that represents a promising agent with a disease-modifying potential in Alzheimer’s disease.

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice.

The data showed that mAb A8 is highly efficacious in APP/PS1 mice as a treatment for AD, and the underlying mechanism may target synaptic pathology by inhibiting the amyloid cascade.